Contraindications of incretin therapy: difference between revisions
Diff·revision 4 → 5·06:09, 9 Dec 2024
Difference between revision 4 and revision 5 of Contraindications of incretin therapy. 5 lines changed; the page grew by 588 bytes.
| Revision 4 — 14:12, 25 Nov 2024 SiteReactionSuz (talk) rm a duplicated category 2,065 bytes ±0 | Revision 5 — 06:09, 9 Dec 2024 ArchiveBot (talk) bot: flag bare reference 2,653 bytes +588 | ||
|---|---|---|---|
| 10 | The labelled contraindications for the class are a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and prior serious hypersensitivity to the product or an excipient. The first derives from rodent C-cell findings and is precautionary; see [[Adverse effects of GLP-1 receptor agonists]].{{r|drucker2018}} | 10 | The labelled contraindications for the class are a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and prior serious hypersensitivity to the product or an excipient. The first derives from rodent C-cell findings and is precautionary; see [[Adverse effects of GLP-1 receptor agonists]].{{r|drucker2018}} |
| 11 | 11 | ||
| + | 12 | A larger set of cautions rather than contraindications covers pancreatitis history, severe pre-existing gastroparesis, pregnancy and breastfeeding, and combination with insulin or sulfonylureas. See [[Pregnancy and incretin therapy]] and [[Hypoglycaemia]].{{r|ada2024}} | |
| + | 13 | ||
| 12 | == Labelled contraindications == | 14 | == Labelled contraindications == |
| 13 | The thyroid contraindication is the distinctive one for this class. Rodent studies showed C-cell hyperplasia and tumours at high exposure; human C cells express the receptor at far lower density and no human signal has been established, but the contraindication is retained as a precaution.{{r|drucker2018}} | 15 | The thyroid contraindication is the distinctive one for this class. Rodent studies showed C-cell hyperplasia and tumours at high exposure; human C cells express the receptor at far lower density and no human signal has been established, but the contraindication is retained as a precaution.{{r|drucker2018}} |
| ⋮ | ⋮ | ||
| 15 | Hypersensitivity contraindications are ordinary for any injected peptide and cover both the active substance and excipients. Reactions specific to a formulation component do not necessarily extend to another product containing the same peptide. | 17 | Hypersensitivity contraindications are ordinary for any injected peptide and cover both the active substance and excipients. Reactions specific to a formulation component do not necessarily extend to another product containing the same peptide. |
| 16 | 18 | ||
| + | 19 | Product labels also carry a substantial set of warnings that are not contraindications — pancreatitis, gallbladder disease, retinopathy in the context of rapid glycaemic improvement, and the perioperative considerations discussed at [[Aspiration risk under anaesthesia]].{{r|ada2024}} | |
| + | 20 | ||
| 17 | == References == | 21 | == References == |
| 18 | {{reflist}} | 22 | {{reflist}} |
| ⋮ | ⋮ | ||
| 23 | [[Category:Contraindications and cautions]] | 27 | [[Category:Contraindications and cautions]] |
| 24 | [[Category:Clinical practice]] | 28 | [[Category:Clinical practice]] |
| + | 29 | [[Category:Adverse effects]] | |
| 25 | 30 |